Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BJT-778 in chronic hepatitis B and hepatitis D coinfection
ACTRN12623000105640Phase 2Recruiting
- Sponsor
- Bluejay Therapeutics
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of brelovitug in Chronic Hepatitis B (CHB) and Chronic Viral Hepatitis B With Delta-Agent (6 cohorts), sponsored by Bluejay Therapeutics. Primary endpoint: Safety and tolerability of BJT-778. Started May 2023; status: recruiting.
02
Drugs
brelovitug
03
Conditions
Chronic Hepatitis B (CHB)Chronic Viral Hepatitis B With Delta-Agent
Beyond the preview
Go deeper on ACTRN12623000105640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000105640.